Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Diagnose af livstruende nekrotiserende blødt vævsinfektioner (NSTI) ved hjælp af indocyaningrøn (ICG) kinetisk modellering

6. november 2026 opdateret af: Eric R. Henderson

Necrotizing soft-tissue infections (NSTIs, a.k.a. "necrotizing fasciitis" or "flesh-eating bacteria") are aggressive infections that can progress rapidly from mild symptoms to sepsis, multi-organ failure, and death. NSTI cases present with non-specific clinical, imaging, and laboratory findings, and standard-of-care techniques for NSTI diagnosis lack sensitivity and specificity, resulting in frequent misdiagnosis and delayed care, which is the single most important predictor of survival. Consequently, the cumulative mortality rate for patients with NSTIs is 20- 30%; a dire need exists for more accurate and rapid detection of NSTIs. Fluorescence-guided surgery is a nascent technology seeking to improve the recognition of anatomical structures and disease processes using fluorescent probes (fluorophores). Indocyanine green (ICG) is an FDA-approved, near-infrared fluorophore with a >60-year safety record for vascular perfusion assessment. A distinguishing histological feature of NSTIs is prominent blood vessel thrombosis in affected tissues. Leveraging these pro-thrombotic effects, our study group has demonstrated in a first-in-human study (NCT04839302) that intravenous administration of ICG and immediate fluorescence imaging reveals prominent signal deficits in NSTI-positive tissues that differentiate significantly with increased signal seen with more common-and less virulent-infections such as cellulitis. We seek now to evaluate this imaging technique on a broader scale and determine if our findings are consistent for patients affected by NSTI-causing pathogens that are not endemic to our region. This prospective, observational, multicenter clinical study will involve video-rate ICG fluorescence imaging of patients suspected of having NSTIs who present to eight tertiary, Level 1 medical centers across the United States (Aim 1). Using dynamic contrast-enhanced fluorescence imaging (DCE-FI), time profiles of ICG fluorescence intensity from different tissue pixels/regions will be extracted and parameterized to extract first-pass kinetic features. These DCE-FI features, which characterize tissue perfusion, will be evaluated alone and in combination with anonymized electronic medical record data to create a DCE-FI-based clinical decision tool and a machine- learning-based fusion (DCE FI+lab/imaging data) tool; these will be compared to identify the most accurate means of diagnosing NSTIs (Aim 2). The best-performing tool will then be evaluated-compared to current diagnostic tests-in a prospective observational clinical study of patients presenting to tertiary emergency departments with findings concerning for NSTIs (Aim 3). Based on our human study, fluorescence imaging will not delay current standard of care. To ensure data fidelity, all sites will use similar: 1) commercial fluorescence imaging systems and accessories; and 2) validated commercial fluorescence reference phantoms. Based on our early results, we have strong confidence that following rigorous testing, ICG DCE-FI will lead to an entirely new methodology for rapid identification of patients with NSTIs, which will ultimately reduce patient morbidity and improve survival.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Observationel

Tilmelding (Anslået)

420

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • California
      • Los Angeles, California, Forenede Stater, 90095
        • Rekruttering
        • University of California, Los Angeles
        • Ledende efterforsker:
          • Christopher Lee, MD
        • Kontakt:
        • Underforsker:
          • Nicholas Bernthal, MD
      • Stanford, California, Forenede Stater, 94305
        • Rekruttering
        • Stanford University
        • Ledende efterforsker:
          • Joseph Forrester, MD
        • Kontakt:
        • Underforsker:
          • Ariel Knight, MD
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30322
        • Rekruttering
        • Emory University/Grady Memorial Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Jaimo Ahn, MD, PhD
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48104
        • Rekruttering
        • University of Michigan
        • Kontakt:
        • Ledende efterforsker:
          • Molly Hunter, MD
        • Ledende efterforsker:
          • Raymond Jean, MD
    • New Hampshire
      • Lebanon, New Hampshire, Forenede Stater, 03756
        • Rekruttering
        • Dartmouth-Hitchcock Medical Center
        • Kontakt:
        • Underforsker:
          • Jonathan Elliot, PhD
        • Underforsker:
          • Samuel S Streeter, PhD
        • Underforsker:
          • Macgregor Montano, PharmD
        • Underforsker:
          • Scott Rodi, MD
        • Ledende efterforsker:
          • Eric R Henderson, MD
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Rekruttering
        • University of Pennsylvania
        • Kontakt:
        • Ledende efterforsker:
          • Niels Martin, MD, PhD
        • Underforsker:
          • Sunil Singhal, MD, PhD
        • Underforsker:
          • Jane Keating, MD
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • Rekruttering
        • University of Pittsburgh Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Kurt Weiss, MD
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37235
        • Rekruttering
        • Vanderbilt University
        • Kontakt:
        • Ledende efterforsker:
          • Jonathan Schoenecker, MD, PhD
        • Underforsker:
          • William Obremskey, MD
        • Underforsker:
          • Eben Rosenthal, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients presenting to the ED or clinic who are considered at intermediate- or high-risk for NSTI.

Beskrivelse

Inclusion Criteria:

  • Age ≥18 years.
  • Clinical suspicion of NSTI based on the local standard of care warranting:
  • Hospital admission for observation due to suspected NSTI; and/or
  • Soft tissue biopsy to rule in/out suspected NSTI; and/or
  • Surgical debridement for suspected NSTI; and/or
  • Specific institutional threshold criteria for triggering NSTI work-up; and
  • Ability to give written informed consent.

Exclusion Criteria:

  • History of allergy to ICG and/or iodine.
  • Pregnant women or nursing mothers.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Determine if tissue perfusion, determined by first-pass ICG fluorescence kinetics, is reliably reduced in the setting of a necrotizing infection compared to a non-necrotizing infection.
Tidsramme: From enrollment to the end of fluorescence imaging (about 1 day)

We will evaluate first-pass fluorescence signal intensity changes from indocyanine green (ICG), a vascular perfusion fluorophore, in the setting of severe soft-tissue infections to determine if ICG fluorescence may be an accurate and reliable diagnostic test for differentiating life-threatening necrotizing infections from non-life-threatening non-necrotizing infections.

From enrollment to the end of fluorescence imaging (about 1 day)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Determine if first-pass ICG fluorescence kinetics in patients with necrotizing infections vary based on the causative bacterial species.
Tidsramme: From enrollment to the end of imaging and lab results (about 30 days)

In patients who had a documented necrotizing soft-tissue infection, we will compare first-pass fluorescence signal intensity changes from ICG based on the predominant causative bacterial species isolated from a patient's infection to determine if ICG signal changes vary by species.

From enrollment to the end of imaging and lab results (about 30 days)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

26. september 2025

Primær færdiggørelse (Anslået)

31. januar 2028

Studieafslutning (Anslået)

31. januar 2028

Datoer for studieregistrering

Først indsendt

10. marts 2025

Først indsendt, der opfyldte QC-kriterier

10. marts 2025

Først opslået (Faktiske)

14. marts 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. marts 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 02002719
  • 1R01AI184513-01 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Data will only be shared in aggregate.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .